Group One Trading
JANX icon

Group One Trading’s Janux Therapeutics JANX Stock Holding History

Group One Trading’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-128
Closed -$2.15K – 7937
2026
Q2 		$1.97K Sell
128
-464
-78% -$6.72K ﹤0.01% 7043
2026
Q1 		$8.23K Buy
+592
New +$8.12K ﹤0.01% 6472
2025
Q3 		– Sell
-12,288
Closed -$299K – 8746
2025
Q2 		$284K Sell
12,288
-699
-5% -$18.4K ﹤0.01% 3977
2025
Q1 		$351K Buy
12,987
+8,015
+161% +$302K ﹤0.01% 3441
2024
Q4 		$266K Buy
+4,972
New +$263K ﹤0.01% 3704
2024
Q3 		– Sell
-381
Closed -$16.6K – 6979
2024
Q2 		$16K Buy
+381
New +$17.9K ﹤0.01% 5372

Other funds holding JANX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Group One Trading's JANX Position: Q3 2026 in Review

Group One Trading sold out of Janux Therapeutics (JANX) in Q3 2026, closing a stake of 128 shares — an estimated $2.15K sold.

Group One Trading first reported a position in JANX in Q2 2024 and held it in 6 quarters. The position peaked at $351K in Q1 2025. 87 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • Group One Trading reported no remaining Janux Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Group One Trading sold 128 Janux Therapeutics shares in Q3 2026, an estimated $2.15K.
  • Group One Trading first reported a position in Janux Therapeutics in Q2 2024 and held it in 6 quarters.
  • Group One Trading's Janux Therapeutics position peaked at $351K in Q1 2025.
  • 87 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.